Noxopharm (ASX: NOX) (‘Noxopharm’) is pleased to announce that its majority-owned U.S. subsidiary company, Nyrada Inc (‘Nyrada’), has received a cash rebate of $486.338K under the Australian Government’s R&D Tax Incentive Scheme which reimburses companies for 43% of approved R&D expenditure. Nyrada was established by Noxopharm to house a number of non-oncology drug assets and Noxopharm currently owns 67.7% of Nyrada.
For more information, download the attached PDF.
Download this document
